Business
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Achieved development milestone under AbbVie collaboration and extended cash runway into early 20
About this update from Xilio Therapeutics, Inc.
[{"type":"image","alt":"Xilio Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Xilio Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":188,"url":"https://media.zenfs.com/en/globenewswire.com/4b2fe3809d51980d292c758894d943af"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h287MUgQH2Cxm2evcFvU1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI2Mw--/https://media.zenfs.com/en/globenewswire.com/4b2fe3809d51980d292c758894d943af","width":300,"height":188},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/h287MUgQH2Cxm2evcFvU1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI2Mw--/https://media.zenfs.com/en/globenewswire.com/4b2fe3809d51980d292c758894d943af","width":300,"height":188}},"lazy":false},{"type":"text","content":"On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2","length":165,"tagName":"p"},{"type":"text","content":"Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting","length":138,"tagName":"p"},{"type":"text","content":"Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1","length":98,"tagName":"p"},{"type":"text","content":"Achieved development milestone under AbbVie collaboration and extended cash runway into early 2028","length":98,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the first quarter ended March 31, 2026.","length":348,"tagName":"p"},{"type":"text","content":"“We ended the first quarter of 2026 with strong momentum across our pipeline of highly differentiated I-O therapies leveraging our best-in-class masking technology,” said René Russo, Pharm.D., president and chief executive officer of Xilio. “XTX501 has the potential to be a foundational backbone therapy for combination regimens across a broad range of solid tumors, and we are on track to advance this program into the clinic this year. In addition, our recent data for our CLDN18.2 pro...